Participated · Series A · Jun 2026

Pie provides a suite of offerings—Growth, AI Search and Front Desk—designed to help small merchants improve visibility, attract customers on local channels, and convert customer engagement into outcomes like calls, bookings and revenue. The company emphasizes partnerships with vertical software platforms to embed its capabilities into tools already used by small businesses, exemplified by a partnership with MoeGo that reached over 10,000 pet-care businesses and delivered an average 15x return on ad spend in initial weeks. Pie launched from stealth in 2025 and, before its public debut, signed up thousands of small-business customers and generated over 100,000 phone calls to client businesses. Operational metrics cited by the company include many customers experiencing 15–20% year-over-year sales growth. With the recent investment from Amex Ventures and its $19.5M Series A led by Lightspeed, Pie plans to expand platform partnerships, broaden its product suite, and grow its team to scale adoption across categories such as auto repair, pet care, fitness and beauty services.

Participated · Equity · May 2026

Capchase provides a vendor financing platform and acts as a lender to help enterprise technology companies close more deals by offering instant financing to buyers. Its platform embeds underwriting, origination, and deal management directly into sales workflows and uses AI agents to generate loan proposals and documents. The company’s Agentic Lending Coordinator collects quotes, POs, emails, and other documents and converts them into executable loan packages while managing multi-party collaboration through signing. Capchase reports that since beta launch customers have condensed an 8-hour process into a 60-second automated workflow. The recent financing will be used to scale its embedded financing infrastructure globally and to roll out more AI-enabled features. The company is headquartered in New York City.

Participated · Series B · May 2026

Panthalassa builds self-propelled, autonomous floating nodes that capture wave energy to generate continuous clean electricity and run AI inference computing onboard, transmitting results to land via low-Earth-orbit satellites. The company has spent about a decade developing its power generation, propulsion, autonomy, and at-sea computing technologies and demonstrated capabilities with Ocean-1, Ocean-2, and Wavehopper prototypes in 2021 and 2024. Panthalassa plans to deploy its Ocean-3 pilot node series in the northern Pacific in 2026 to demonstrate AI inference at sea and to refine manufacturing ahead of commercial deployments in 2027. The platform uses the ocean for free supercooling to extend chip lifetimes and avoids transmitting power to shore by performing computing onboard. The company is a public benefit corporation headquartered in Portland, Oregon, and recently raised $140 million in a Series B to complete a pilot manufacturing facility and accelerate initial deployments.

Participated · Series A · Jul 2025

Folio is a modern procure-to-pay platform for hotels that combines a managed marketplace (Folio Buy), AI-powered invoice processing (Folio Bills), and streamlined payments (Folio Pay). The company emphasizes rapid implementations and AI-driven workflows to save teams time and money. The recent Series A will help Folio continue to power profitability at hotels and deliver even faster implementations. Since its public debut at HITEC 2024, where it won the E20X Judge’s Choice Award, Folio has expanded quickly and now powers purchasing across hundreds of hotels. It is on track to handle nearly half a billion dollars in annual purchasing volume. The founding team brings experience in financial technology, e-commerce, hospitality, and applied AI; Kate Adamson is CEO and Co-Founder.

Participated · Series A · May 2025

Somite.ai develops large-scale foundation models for human stem cells and a full-stack platform to accelerate discovery and optimization of cell therapies. The company’s proprietary capsule-based data generation platform produces differentiation data at approximately one‑thousandth the cost of traditional methods, enabling dense, causal datasets for training powerful predictive models. Somite combines low-cost data generation, large-scale model training, and model-driven discovery to compress development timelines for cell therapies. The company announced a collaboration with AMD Ventures to pair its platform with AMD Instinct GPUs, boosting compute for model training and exploring optimization of software tools for biological data. The founding team includes repeat AI entrepreneur Dr. Micha Breakstone, the Head of the Fundamental AI Group at MIT, and three National Academy of Science members. Somite is based in Boston, launched operations in January 2024, and has raised approximately $60M to date. Somite AI builds DeltaStem, a foundation-model platform and associated tools to design and optimize cell differentiation protocols for scalable human cell production. Its proprietary capsule technology generates cell state transition and signaling data at roughly 1,000x the efficiency of existing methods, which feeds DeltaStem. The company plans to use the platform to advance internal therapeutic programs including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders. Somite positions DeltaStem as a generalizable foundation model for developmental biology, aiming to deliver protocols with improved purity, scalability, and reliability. The company reported closing a Series A financing of more than $47 million to accelerate platform development and key programs. Founders and scientific leadership include Dr. Micha Breakstone and Dr. Jonathan Rosenfeld alongside noted academic co‑founders such as Olivier Pourquié, Allon Klein, Jay Shendure, and Cliff Tabin. Somite Therapeutics builds AI foundation models (AlphaStem) that generate large datasets to design and produce human tissues for cell-replacement therapies. The company focuses on developing scalable cell therapies for diseases such as diabetes, obesity, and muscular dystrophies, and its pipeline includes SMT-M01 for Duchenne muscular dystrophy and SMT-B01 for metabolic disorders. Somite plans to use generated data to iteratively improve its platform and expand therapy creation across broader indications. The team is led by founder and CEO Dr. Micha Breakstone and includes senior scientific and translational leaders and prominent academic co-founders. Financially, Somite completed a $4.8M extension of its pre-seed round, bringing total funds raised to over $10M. The new capital is earmarked to expedite data generation for AlphaStem, advance SMT-M01 toward the clinic, initiate the SMT-B01 program, and begin research with hypoimmune cell lines. Somite is a Boston, MA–based developer of AI for stem cell biology building foundation models to produce human tissue for cell therapies. Its proprietary AlphaStem AI platform generates massive datasets that improve the platform and enable therapy creation through rapid optimization cycles. The company focuses on producing cells derived from somites — including muscle, brown adipose, cartilage, bone, tendon, and dermis — to address diseases such as diabetes, obesity, and muscular dystrophies. Somite is also pioneering a computational digital twin of the embryo that draws on scRNA-Seq, scATAC-seq, and gene expression databases to mirror development and identify regulators of cell differentiation. The team combines AI and developmental biology expertise and includes CEO and co-founder Micha Breakstone alongside scientific co-founders such as Olivier Pourquie, Allon Klein, and Cliff Tabin. The company raised funding to continue development of AlphaStem and advance its platform.